期刊
MEDICAL CLINICS OF NORTH AMERICA
卷 97, 期 3, 页码 369-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2012.12.012
关键词
Alzheimer disease; Cerebrospinal fluid; Biomarkers; Early diagnosis; Amyloid of A beta; Tau protein
This article gives an updated account of the clinical application of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease (AD). The clinically most relevant biomarkers, total tau, phospho-tau and A beta 42 are discussed, and how they may be used, together with other diagnostic investigations, to make a predementia diagnosis of AD. Recent findings in sporadic and genetic preclinical AD are also discussed and, more specifically, what the biomarkers have taught us on the sequence of events in the pathogenic process underlying AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据